Last reviewed · How we verify

Lignospan Forte (Lidocaine Hydrochloride)

Fresenius Kabi · FDA-approved approved Small molecule Quality 68/100

Lidocaine stabilizes neuronal membrane by inhibiting ionic fluxes required for impulse initiation and conduction.

Lidocaine Hydrochloride (Lignospan Forte) is a topical amide-type local anesthetic indicated for anesthesia of irritated or inflamed mucous membranes of the mouth and pharynx. It stabilizes neuronal membranes by inhibiting ionic fluxes required for impulse initiation and conduction, with rapid hepatic metabolism and renal excretion. Contraindicated in patients with hypersensitivity to amide-type local anesthetics; concurrent use with methemoglobinemia-inducing drugs increases risk of this serious adverse effect. Modest hypotension may occur with excessive blood levels, but adverse effects are generally minimal when recommended dosages are not exceeded.

At a glance

Generic nameLidocaine Hydrochloride
SponsorFresenius Kabi
Drug classlocal anesthetic, amide type
Targetneuronal membrane ionic channels
ModalitySmall molecule
Therapeutic areaNeuroscience
PhaseFDA-approved
First approval1948

Mechanism of action

Lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. Excessive blood levels may cause changes in cardiac output, total peripheral resistance, and mean arterial pressure, attributable to a direct depressant effect on various cardiovascular system components. The net effect is normally a modest hypotension when recommended dosages are not exceeded.

Approved indications

Boxed warnings

Common side effects

Drug interactions

Patents

PatentExpiryType
93706222035-09-28Method of Use
87594012026-07-24Formulation
93583382035-04-27Method of Use
85406652029-10-22Method of Use

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
FDA Orange BookPatents + exclusivity

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: